Kura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index (NBI) contains securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NBI is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For more information about the NBI, visit https://indexes.nasdaqomx.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The company’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Pete De Spain
Vice President, Investor Relations &
Kura Oncology, Inc.
Robert H. Uhl
Westwicke Partners, LLC